Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research and Development Limited
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer
*To determine an optimal treatment regimen of the combination of lapatinib and pemetrexed. *To evaluate the overall response rate after two treatment cycles in patients receiving lapatinib in combinat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
Chemotherapy plus Lapatinib (GW572016) or Trastuzumab or both in HER2+ Primary Breast Cancer. A Randomized Phase IIb study with Biomarker Evaluation
To evaluate the percentage of pathological complete responses (pCR) in the breast and in the lymph nodes
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
NKV110721, A Study of Single Dose Intravenous Casopitant in Combination with Ondansetron and Dexamethasone for the Prevention of Oxaliplatin-Induced Nausea and Vomiting
To demonstrate the superiority of triple therapy, single-dose 90 mg IV casopitant in combination with ondansetron and dexamethasone, over dual therapy ondansetron and dexamethasone for the prevention ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome
The primary objective is to determine whether solabegron provides adequate relief of IBS pain or discomfort compared to placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4